These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25060252)

  • 21. Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.
    Guglielmelli P; Pietra D; Pane F; Pancrazzi A; Cazzola M; Vannucchi AM; Tura S; Barosi G
    Leuk Res; 2017 Jul; 58():63-72. PubMed ID: 28460339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
    Spivak JL
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):1-5. PubMed ID: 12682874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myeloproliferative neoplasms related glomerulopathy].
    Paule R; Ponsoye M; Gueutin V; Deray G; Izzedine H
    Rev Med Interne; 2013 Jun; 34(6):369-72. PubMed ID: 23357690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of beta-catenin in chronic myeloproliferative disorders.
    Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
    Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone morbidity in chronic myeloproliferative neoplasms.
    Farmer S; Ocias LF; Vestergaard H; Broesby-Olsen S; Hermann AP; Frederiksen H
    Expert Rev Hematol; 2015 Aug; 8(4):447-56. PubMed ID: 26036168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.
    Barosi G; Vannucchi AM; De Stefano V; Pane F; Passamonti F; Rambaldi A; Saglio G; Barbui T; Tura S
    Leuk Res; 2014 Feb; 38(2):155-60. PubMed ID: 24378116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chronic myeloproliferative syndromes].
    de Ozalla CB; García Suárez J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():28-36. PubMed ID: 10422448
    [No Abstract]   [Full Text] [Related]  

  • 30. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
    Skotnicki AB; Wolska-Smoleń T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
    Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
    Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
    Thiele J; Kvasnicka HM; Vardiman J
    Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.
    Geyer HL; Kosiorek H; Dueck AC; Scherber R; Slot S; Zweegman S; Te Boekhorst PA; Senyak Z; Schouten HC; Sackmann F; Fuentes AK; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Döhner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Paoli C; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Cannon K; Birgegard G; Xiao Z; Xu Z; Zhang Y; Sun X; Xu J; Kiladjian JJ; Zhang P; Gale RP; Mesa RA
    Haematologica; 2017 Jan; 102(1):85-93. PubMed ID: 27540137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986.
    Heudes D; Carli PM; Bailly F; Milan C; Mugneret F; Petrella T
    Nouv Rev Fr Hematol (1978); 1989; 31(5):375-8. PubMed ID: 2587208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
    Tefferi A; Vardiman JW
    Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.